Cartesian Therapeutics (RNAC) Other Gross PP&E Adjustments (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with $8.7 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 53.88% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 53.88% increase, with the full-year FY2025 number at $8.7 million, up 53.88% from a year prior.
- Other Gross PP&E Adjustments was $8.7 million for Q4 2025 at Cartesian Therapeutics, down from $11.5 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $11.5 million in Q3 2025 to a low of -$6.8 million in Q4 2021.
- A 5-year average of $310100.0 and a median of -$1.9 million in 2022 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: crashed 104.48% in 2023, then skyrocketed 1024.5% in 2025.
- Cartesian Therapeutics' Other Gross PP&E Adjustments stood at -$6.8 million in 2021, then skyrocketed by 84.03% to -$1.1 million in 2022, then plummeted by 104.48% to -$2.2 million in 2023, then soared by 353.42% to $5.7 million in 2024, then skyrocketed by 53.88% to $8.7 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Other Gross PP&E Adjustments are $8.7 million (Q4 2025), $11.5 million (Q3 2025), and $10.6 million (Q2 2025).